RENAL CARE & DATA LINKAGE OF TASMANIAN KIDNEY DISEASE CASES
With
Professor Matthew Jose, Kidney Specialist
Head of Unit, Nephrology, Royal Hobart Hospital &
Professor of Medicine, University of Tasmania
Tasmania, Australia
RESEARCHER PROFILE
Filmed in Hobart, Tasmania, Australia | March 2026
Professor Matthew Jose is a Renal Physician & Head of the Renal Unit at the Royal Hobart Hospital, and Professor of Medicine for the University of Tasmania.
Winner of the 2021 Rural Science Award from the Australia and New Zealand Society of Nephrology, he has worked in regional, rural and remote Australian locations for nearly 20 years as a Renal Physician, including the Northern Territory.
He is currently Chairperson of the Tasmanian Statewide Kidney Clinical Network and a member of national clinical guideline groups including Therapeutic Guidelines and CARI guidelines kidney stone working group, as well as a member of the KidGEN (Kidney Genetics) national steering committee.
He has established the first regional young adult transplant clinic for young Tasmanians with a kidney transplant transferring from paediatric to adult care.
Professor Jose’s research has been funded by Australia’s NHMRC and MRFF, as well as Royal Hobart Hospital Research Foundation in Tasmania.
Source: Supplied and adapted
https://orcid.org/0000-0002-9589-0071
-
Identification & characterisation of molecular drivers of therapeutic resistance
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
-
Pathogenicity, modelling & treatment of inherited retinal Stargardt disease
Dr Di Huang is a Research Associate at the Lions Eye Institute (LEI), working with A/Professor Fred Chen and Dr Sam McLenachan. Her research focuses on developing a robust platform of retinal pigment epithelium cells and retinal organoids derived from patient-specific induced pluripotent stem cells to model inherited retinal diseases, particularly Stargardt disease (STGD1).
